Late gadolinium enhancement on cardiac magnetic resonance and phenotypic expression in hypertrophic cardiomyopathy - 06/08/11
, Sergio Bongioanni, MD a, Amedeo Chiribiri, MD b, Stefano Leuzzi, MD c, Elisabetta Lardone, MD a, Paolo Di Donna, MD c, Alfredo Pizzuti, MD a, Stefania Luceri, MD a, Federico Cesarani, MD c, Barbara Mabritto, MD a, Giuseppe Biondi Zoccai, MD d, Rodolfo Bonamini, MD d, Fiorenzo Gaita, MD dRésumé |
Background |
Cardiac magnetic resonance (CMR) imaging with late gadolinium enhancement (LGE) can identify areas of myocardial fibrosis in vivo in patients with hypertrophic cardiomyopathy (HCM). The aim of this study was to examine the association between clinical-morphological variables, risk factor for sudden death, and LGE findings in a consecutive, unselected population of HCM patients.
Methods |
From January 2005 to August 2009, 124 HCM patients (53 ± 17 years, 86 men) were prospectively evaluated with CMR examination, assessing left ventricular (LV) hypertrophy, function, and LGE.
Results |
In univariate analysis, patients were divided into tertiles according to the number of segments positive for LGE (first tertile, 0.3 ± 0.4; second tertile, 2.2 ± 0.4; third tertile, 5.2 ± 1.9 segments). Male gender (P = .05), maximum LV wall thickness (P = .002), nonsustained ventricular tachycardia (P = .001), ejection fraction <50% (P = .02), LV mass (P = .02), left atrium dilation (P = .04), perfusion defects (P ≤ .001), and telesystolic volume (P = .04) were all positively related with the number of segments of LGE. In multivariable analysis, male gender (P = .007), maximum LV wall thickness (P = .006), LV mass (P = .031), and perfusion alterations (P = .017) were independent predictors of LGE extent.
Conclusions |
Our study shows an independent association, even at multivariate analysis, between the entity of LGE and maximum LV wall thickness, mass, and perfusion defects in patients with HCM. Whether the presence and the extent of LGE translates into clinical events later on awaits further long-term follow-up studies.
Le texte complet de cet article est disponible en PDF.Plan
Vol 161 - N° 6
P. 1073-1077 - juin 2011 Retour au numéro
Article précédent
- Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: Analysis from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Trials
- Peter S. Pang, Mihai Gheorghiade, Jamil Dihu, Karl Swedberg, Sadiya Khan, Aldo P. Maggioni, Liliana Grinfeld, Faiez Zannad, John C. Burnett, John Ouyang, James E. Udelson, Marvin A. Konstam
- A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF)
- Emerson C. Perin, Guilherme V. Silva, Timothy D. Henry, Maria G. Cabreira-Hansen, Warren H. Moore, Stephanie A. Coulter, J. Patrick Herlihy, Marlos R. Fernandes, Benjamin Y.C. Cheong, Scott D. Flamm, Jay H. Traverse, Yi Zheng, Deirdre Smith, Sandi Shaw, Lynette Westbrook, Rachel Olson, Dipsu Patel, Amir Gahremanpour, John Canales, William K. Vaughn, James T. Willerson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?